EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 84 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $109 | -45.8% | 355,867 | +24.6% | 0.01% | -55.0% |
| Q2 2023 | $201 | +14.9% | 285,677 | +46.1% | 0.02% | +17.6% |
| Q1 2023 | $175 | +90.2% | 195,504 | +150.5% | 0.02% | +54.5% |
| Q4 2022 | $92 | -100.0% | 78,031 | -57.8% | 0.01% | -90.9% |
| Q4 2021 | $960,000 | -3.0% | 184,980 | +24.8% | 0.12% | +19.8% |
| Q3 2021 | $990,000 | +45.4% | 148,185 | +85.4% | 0.10% | +31.2% |
| Q2 2021 | $681,000 | +189.8% | 79,912 | +200.7% | 0.08% | +97.4% |
| Q1 2021 | $235,000 | -85.9% | 26,575 | -80.4% | 0.04% | -85.7% |
| Q4 2020 | $1,666,000 | +59.3% | 135,536 | +5.5% | 0.27% | +56.9% |
| Q3 2020 | $1,046,000 | +377.6% | 128,491 | +463.5% | 0.17% | +42.6% |
| Q2 2020 | $219,000 | +14.1% | 22,802 | +76.6% | 0.12% | +454.5% |
| Q4 2019 | $192,000 | -3.5% | 12,915 | -33.5% | 0.02% | -18.5% |
| Q3 2019 | $199,000 | -59.1% | 19,434 | -57.7% | 0.03% | -50.9% |
| Q2 2019 | $487,000 | – | 45,919 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,787,091 | $20,462,000 | 6.02% |
| INTERWEST VENTURE MANAGEMENT CO | 1,599,592 | $18,315,000 | 3.89% |
| NEXTHERA CAPITAL LP | 263,600 | $3,018,000 | 1.54% |
| SPHERA FUNDS MANAGEMENT LTD. | 385,301 | $4,412,000 | 0.86% |
| RA Capital Management | 354,200 | $4,056,000 | 0.50% |
| DAFNA Capital Management LLC | 35,977 | $412,000 | 0.35% |
| Boxer Capital, LLC | 138,331 | $1,584,000 | 0.35% |
| SABBY MANAGEMENT, LLC | 238,907 | $2,735,000 | 0.15% |
| Monashee Investment Management LLC | 31,500 | $361,000 | 0.14% |
| Lombard Odier Asset Management (USA) Corp | 100,000 | $1,145,000 | 0.11% |